Navigation Links
Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar®
Date:10/15/2010

PITTSBURGH, Oct. 15 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approvals from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for the generic versions of Hyzaar® Tablets, 50 mg/12.5 mg and 100 mg/25 mg, and Cozaar® Tablets, 25 mg, 50 mg and 100 mg, both antihypertensives. Merck and Co. Inc.'s Hyzaar® is known generically as Losartan Potassium and Hydrochlorothiazide (HCTZ) Tablets and Merck Research Laboratories' Cozaar® is known generically as Losartan Potassium Tablets.

Losartan Potassium and HCTZ Tablets, 50 mg/12.5 mg and 100 mg/25 mg, had U.S. sales of approximately $570 million and Losartan Potassium Tablets had U.S. sales of approximately $940 million for the 12 months ending June 30, 2010, according to IMS Health. Both products are available for immediate shipment. Mylan Pharmaceuticals received final FDA approval and launched the 100 mg/12.5 mg strength of Losartan Potassium and HCTZ Tablets on April 6, 2010.

Currently, Mylan has 151 ANDAs pending FDA approval representing $92.9 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $21.9 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
2. Mylan Receives Approval for Fludarabine Phosphate Injection, USP
3. Mylan Launches Generic Version of Wellbutrin XL® Tablets
4. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
5. Mylan Receives Approval for Generic Version of Prograf® Capsules
6. Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
7. Mylan Announces Completion of Add-On Offering of Senior Notes
8. Mylan Announces Pricing of Add-On Offering of Senior Notes
9. Mylan Launches the Generic Version of Solodyn®, 45 mg, 90 mg and 135 mg Tablets, Announces Settlement Agreement with Medicis
10. Mylan Announces Settlement Agreement for Namenda®
11. Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, in ... Greisch , Hill-Rom,s president and chief executive officer, is scheduled ... live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . ... of the live event through September 13, 2017. ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... Two residents from the ... a video designed to encourage lawmakers to protect Medicaid funding. , The ... Assisted Living (AHCA/NCAL), highlights the story of Chuck and Cathy Schwarz, a couple who ...
(Date:6/27/2017)... York, NY (PRWEB) , ... June 27, 2017 ... ... and marketing experts to contribute to an upcoming case studies guidebook. This guidebook ... her organization. , This book will include articles, case studies and how-to’s that ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and maintenance strategies ... experience in these popular periodontal procedures. Drs. Toback and Urbanski practice as experienced ...
(Date:6/27/2017)... ... ... Hammer Strength, the world’s leading performance strength training brand, and the National ... the NBSCA Strength & Conditioning Coach of the Year. , In its 11th ... select the coach who embodies the highest level of excellence and outstanding service to ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... . Orthodontics is a dental specialty that focuses on treating alignment and occlusion ... improved aesthetics and function. , North Hollywood dentist , Dr. Garemani, ...
Breaking Medicine News(10 mins):